ANO2

Across TCGA pan-cancer cohorts, ANO2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANO2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANO2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANO2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where ANO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.662	0.963	.003	42	view →
LUAD	DFS	Tertile	All	0.337	0.758	.005	15	view →
UCEC	OS	Tertile	All	1.000	0.909	.021	14	view →
HNSC	DFS	Quartile	All	0.903	0.607	.007	14	view →
PDAC	OS	Quartile	II,III,IV	0.754	0.317	.004	6	view →
LSCC	OS	Tertile	III,IV	0.918	0.521	.047	4	view →
GBM	OS	Quartile	All	0.988	0.803	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANO2–CCRCC (OS)

Open the CCRCC breakdown →